Experience

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…

Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised the placing agents for the top-up placement of up to 97,000,000 shares in Innovent Biologics, Inc. for a total consideration of approximately HK$2.4 billion. Davis Polk…

Davis Polk advised TPG Capital, the private equity platform of global alternative asset firm TPG, on its acquisition of Convey Health Solutions from New Mountain Capital and related…

Davis Polk is advising Duff & Phelps as financial adviser to the Board of Directors of Elanco Animal Health Incorporated in connection with its approximately $7.6 billion acquisition of…

Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet. Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…